Clinical trial
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients…
NCT00478647 · Shire, Industry · Completed
Key facts
| NCT number | NCT00478647 |
|---|---|
| Title | Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase |
| Official title | A Multicenter Open-Label Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Gaucher Disease |
| Intervention type | Biological |
| Interventions | GA-GCB (velaglucerase alfa) |
| Enrollment | 40 |
| Start date | Jul 25, 2007 |
| Primary completion | Jun 26, 2009 |
| Completion | Jun 26, 2009 |
| First posted | May 25, 2007 |
| Last update posted | Jun 10, 2021 |
| Countries | Israel, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: